Skip to main content

Fibrodysplasia Ossificans Progressiva clinical trials at UCSF

2 in progress, 0 open to eligible people

Showing trials for
  • An Efficacy and Safety Study of Palovarotene for the Treatment of FOP

    Sorry, in progress, not accepting new patients

    Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.

    San Francisco, California and other locations

  • An Open-Label Extension Study of Palovarotene Treatment in FOP

    Sorry, in progress, not accepting new patients

    Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability. In this study, the ability of palovarotene to prevent HO formation will be evaluated.

    San Francisco, California and other locations

Last updated: